Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07222670 · ClinicalTrials.gov registry record · Phase 2
A Study Assessing Safety, Tolerability, and Efficacy of INNA-051 in Preventing Respiratory Illness Due to Viral Infections in Healthy Adults 18 to 45 Years of Age
A Phase 2 study of Viral Respiratory Infection and Viral Respiratory Illnesses, sponsored by ENA Respiratory Pty.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 1,100
- Enrollment target
- 5
- Study locations
NCT07222670: Recruiting Phase 2 study of Viral Respiratory Infection and Viral Respiratory Illnesses, sponsored by ENA Respiratory Pty.
NCT07222670 is a Phase 2 study of Viral Respiratory Infection and Viral Respiratory Illnesses that is actively recruiting participants, run by ENA Respiratory Pty. The registered enrollment target is 1,100 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (727% higher). The trial reports 5 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07222670, a Phase 2 study of Viral Respiratory Infection and Viral Respiratory Illnesses, is actively recruiting participants, sponsored by ENA Respiratory Pty.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 1,100 participants
- Enrollment target
- 5
- Study locations
Study Summary
Acute upper and lower respiratory infections are a major public health problem and a leading cause of morbidity and mortality worldwide. The purpose of this trial is to assess the safety of the investigational agent INNA-051, given intranasally, and its potential effectiveness in reducing the occurrence, severity, and/or the duration of illness resulting from respiratory virus infections. The trial will enroll generally healthy adults (age 18 - 45 years) who are at risk for exposure to viral respiratory infection, for example, due to living conditions or occupation. Participants will be treated with INNA-051 or placebo once weekly for 4 weeks (Part A) or 12 weeks (Part B) during the respiratory virus season.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG INNA-051
Study Locations (5)
North Carolina
- Accellacare of Raleigh - Raleigh
- Accellacare of Piedmont HealthCare - Statesville
- Accellacare - Wilmington - Wilmington
Maryland
- Center for Vaccine Development and Global Health (CVD) - Baltimore
- Naval Medical Research Command (NMRC) - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,100 participants |
| Start Date | 2025-12-04 |
| Est. Completion | 2027-02-09 |
| Phase | Phase 2 |
What NCT07222670 shows while recruiting
NCT07222670 is an interventional study that assigns participants to a tested intervention. Its 1,100 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (727% higher).
The record links to 2 conditions, with Viral Respiratory Infection appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07222670 lists 5 locations in 2 states (North Carolina, Maryland).
Frequently Asked Questions
What is clinical trial NCT07222670 about?
NCT07222670 is a clinical study titled "A Study Assessing Safety, Tolerability, and Efficacy of INNA-051 in Preventing Respiratory Illness Due to Viral Infections in Healthy Adults 18 to 45 Years of Age". Acute upper and lower respiratory infections are a major public health problem and a leading cause of morbidity and mortality worldwide. The purpose of this trial is to assess the safety of the investigational agent INNA-051, given intranasally, and its potential effectiveness in reducing the occurr...
What is the current status of trial NCT07222670?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 1,100 participants. The study started on 2025-12-04. Estimated completion is 2027-02-09.
What conditions does trial NCT07222670 study?
This clinical trial studies the following conditions: Viral Respiratory Infection, Viral Respiratory Illnesses.
What interventions are being tested in trial NCT07222670?
The interventions under investigation include: Placebo (OTHER), INNA-051 (DRUG).
Who is sponsoring clinical trial NCT07222670?
This trial is sponsored by ENA Respiratory Pty, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07222670 being conducted?
This trial has 5 study locations across Maryland, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07222670's enrollment target sits among peer trials
1,100 21st of 2000 higher than 1,980 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00710112 · 1,100 participants
Genetic Variants and Susceptibility to Diseases of Prematurity in Very Low Birth-Weight Infants
- NCT02688517 · 1,100 participants
Targeted Genomic Analysis of Blood and Tissue Samples From Patients With Cancer
- NCT04743765 · 1,100 participants · NA
HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 Trial
- NCT05638581 · 1,100 participants · Phase 3
Trauma Resuscitation With Low-Titer Group O Whole Blood or Products
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI